Literature DB >> 15744142

Compliance and persistency in glaucoma follow-up treatment.

Gail F Schwartz1.   

Abstract

PURPOSE OF REVIEW: To summarize research published between 1980 and October 2004 regarding compliance (the extent to which patients' behaviors correspond with providers' recommendations) and persistency (total time on therapy) in patients diagnosed with open-angle glaucoma or ocular hypertension; to suggest approaches ophthalmologists might consider to improve compliance and persistency; and to identify areas warranting future research. RECENT
FINDINGS: Medication compliance, the focus of most compliance-related research, has been measured using a variety of methods including patient self-reports, the medication possession ratio, and electronic monitoring. Noncompliance rates of at least 25% commonly have been reported. The primary obstacles to medication compliance appear to be situational/environmental (e.g., being away from home or a change in routine) or related to the medication regimen (e.g., side effects or complexity). Persistency with ocular hypotensive therapies has been found to be poor. Retrospective cohort studies using survival analyses have reported that fewer than 25% of patients are persistent over 12 months.
SUMMARY: Accurately assessing patient compliance and persistency is important to optimizing patient care. Physicians may mistake either medication noncompliance or lack of persistency with poor efficacy. Such errors would likely increase health care costs if they result in unnecessary changes to a patient's therapeutic regimen or in surgery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15744142     DOI: 10.1097/01.icu.0000156139.05323.26

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  34 in total

1.  Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications.

Authors:  Javier Soto
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Microprocessor controlled compliance monitor for eye drop medication.

Authors:  M M Hermann; M Diestelhorst
Journal:  Br J Ophthalmol       Date:  2006-03-15       Impact factor: 4.638

3.  A cost minimisation analysis comparing iStent accompanying cataract surgery and selective laser trabeculoplasty versus topical glaucoma medications in a public healthcare setting in New Zealand.

Authors:  Kelvin Ngan; Ewan Fraser; Sophie Buller; Alex Buller
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-21       Impact factor: 3.117

4.  Patient acceptance to smartphone technology to monitor and improve glaucoma health-care outcomes.

Authors:  R M H Lee; J D Oleszczuk; J N Hyer; G Gazzard
Journal:  Eye (Lond)       Date:  2014-02-14       Impact factor: 3.775

5.  Twenty-four hour efficacy with the dorzolamide/timolol-fixed combination compared with the brimonidine/timolol-fixed combination in primary open-angle glaucoma.

Authors:  A G P Konstas; L Quaranta; D B Yan; D G Mikropoulos; I Riva; N K Gill; K Barton; A-B Haidich
Journal:  Eye (Lond)       Date:  2011-09-30       Impact factor: 3.775

6.  Determinants of medication adherence to topical glaucoma therapy.

Authors:  Laura E Dreer; Christopher Girkin; Steven L Mansberger
Journal:  J Glaucoma       Date:  2012 Apr-May       Impact factor: 2.503

7.  Electronic compliance monitoring of topical treatment after ophthalmic surgery.

Authors:  Manuel Marcel Hermann; Can Ustündag; Michael Diestelhorst
Journal:  Int Ophthalmol       Date:  2010-04-07       Impact factor: 2.031

8.  Patient persistence with first-line antiglaucomatous monotherapy.

Authors:  Alfonso Arias; Konrad Schargel; Fernando Ussa; Maria I Canut; Amelia Y Belén Robles; Belén Martí Sánchez
Journal:  Clin Ophthalmol       Date:  2010-04-26

9.  Feasibility of motivational interviewing delivered by a glaucoma educator to improve medication adherence.

Authors:  Paul F Cook; Robert W Bremer; A J Ayala; Malik Y Kahook
Journal:  Clin Ophthalmol       Date:  2010-10-05

Review 10.  Use of fixed-dose combination drugs for the treatment of glaucoma.

Authors:  Albert S Khouri; Tony Realini; Robert D Fechtner
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.